NASDAQ: ARTV

Artiva Biotherapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ARTV. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 10:56 UTC.

What Artiva Biotherapeutics, Inc. does

The company is a clinical-stage biotechnology firm developing natural killer cell-based therapies for autoimmune diseases and cancers. Its lead product, AlloNK, is an off-the-shelf allogeneic NK cell therapy designed to work with monoclonal antibodies to deplete B-cells in patients with conditions like rheumatoid arthritis and Sjogren's disease. AlloNK was the first allogeneic off-the-shelf NK cell therapy to receive regulatory clearance for autoimmune disease trials in the United States and has received FDA Fast Track designation in rheumatoid arthritis and lupus nephritis.

Summarized from Artiva Biotherapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-05-19
Return on equity	-35.03%

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-07

2026-10-07Chief Executive OfficerSale-23,463$168.9K
2026-10-06Chief Tech Operations OfficerSale-10,340$70.7K
2026-10-06Chief Executive OfficerSale-61,696$421.8K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

RA CAPITAL MANAGEMENT, L.P.17,955,642$174.17M+82.2%
VIKING GLOBAL INVESTORS LP2,604,166$25.26MNEW
Blackstone Inc.2,403,437$23.31MNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-05-19Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-12-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-01-29Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Yahoo2026-09-17
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche
Seeking Alpha Feed2026-08-18
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Artiva Biotherapeutics, Inc. do?

The company is a clinical-stage biotechnology firm developing natural killer cell-based therapies for autoimmune diseases and cancers.

When did ARTV last file with the SEC?

Artiva Biotherapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-19. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 10:56 UTC. This page is also available as JSON at /api/data?ticker=ARTV and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ARTV and 5,000+ tickers.

Create a free account — keep ARTV

For your agent

GET /api/data?ticker=ARTV

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt